Literature DB >> 29207766

Successful Management of Urosepsis with Ceftriaxone+Sulbactam+EDTA: A Case Report of Penem Sparing Approach.

Amit Bery1, Candy Sodhi2, Rishu Bhanot3.   

Abstract

Over the past decade, the Anti-Microbial Resistance (AMR) among members of Enterobacteriaceae family is on rise mainly due to rapid spread of strains producing Extended-Spectrum Beta-Lactamases (ESBLs) and Metallo Beta-Lactamases (MBLs). Hence, the choice of drugs available for these resistant strains is diminishing and their treatment is becoming more challenging. This is a case of complicated Urinary Tract Infection (cUTI) due to ESBL producing E. coli leading to septic shock which was successfully managed with Antibiotic Adjuvant Entity (AAE), a combination of ceftriaxone+sulbactam+EDTA.

Entities:  

Keywords:  Antibiotic adjuvant entity; Multi-drug resistance; Sepsis; Urinary tract infection

Year:  2017        PMID： 29207766      PMCID： PMC5713788          DOI： 10.7860/JCDR/2017/29146.10661

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN： 0973-709X


  9 in total

Review 1.  Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria.

Authors:  Ann Pallett; Kieran Hand
Journal:  J Antimicrob Chemother       Date:  2010-11       Impact factor: 5.790

Review 2.  Bacterial characteristics of importance for recurrent urinary tract infections caused by Escherichia coli.

Authors:  Karen Ejrnæs
Journal:  Dan Med Bull       Date:  2011-04

3.  Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study.

Authors:  Karthikeyan K Kumarasamy; Mark A Toleman; Timothy R Walsh; Jay Bagaria; Fafhana Butt; Ravikumar Balakrishnan; Uma Chaudhary; Michel Doumith; Christian G Giske; Seema Irfan; Padma Krishnan; Anil V Kumar; Sunil Maharjan; Shazad Mushtaq; Tabassum Noorie; David L Paterson; Andrew Pearson; Claire Perry; Rachel Pike; Bhargavi Rao; Ujjwayini Ray; Jayanta B Sarma; Madhu Sharma; Elizabeth Sheridan; Mandayam A Thirunarayan; Jane Turton; Supriya Upadhyay; Marina Warner; William Welfare; David M Livermore; Neil Woodford
Journal:  Lancet Infect Dis       Date:  2010-08-10       Impact factor: 25.071

4.  The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials.

Authors:  Mayuri Trivedi; Mayur Trivedi; Vipul Patel; Rajeev Soman; Camilla Rodriguez; Tanu Singhal
Journal:  J Assoc Physicians India       Date:  2012-08

5.  Incidence and antibiotic prescription rates for common infections in patients with diabetes in primary care over the years 1995 to 2003.

Authors:  L M A J Venmans; E Hak; K J Gorter; G E H M Rutten
Journal:  Int J Infect Dis       Date:  2009-02-08       Impact factor: 3.623

6.  A Combination Strategy of Ceftriaxone, Sulbactam and Disodium Edetate for the Treatment of Multi-Drug Resistant (MDR) Septicaemia: A Retrospective, Observational Study in Indian Tertiary Care Hospital.

Authors:  Umakant Nagashetty Patil; Kiran Lakkol Jambulingappa
Journal:  J Clin Diagn Res       Date:  2015-11-01

7.  Community acquired multi-drug resistant clinical isolates of Escherichia coli in a tertiary care center of Nepal.

Authors:  Shamshul Ansari; Hari Prasad Nepal; Rajendra Gautam; Sony Shrestha; Puja Neopane; Ganga Gurung; Moti Lal Chapagain
Journal:  Antimicrob Resist Infect Control       Date:  2015-05-01       Impact factor: 4.887

Review 8.  Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management.

Authors:  Orna Nitzan; Mazen Elias; Bibiana Chazan; Walid Saliba
Journal:  Diabetes Metab Syndr Obes       Date:  2015-02-26       Impact factor: 3.168

9.  Safety and efficacy of a novel drug elores (ceftriaxone+sulbactam+disodium edetate) in the management of multi-drug resistant bacterial infections in tertiary care centers: a post-marketing surveillance study.

Authors:  Manu Chaudhary; Mohd Amin Mir; Shiekh Gazalla Ayub
Journal:  Braz J Infect Dis       Date:  2017-04-01       Impact factor: 3.257
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.